公开(公告)号：EP3601253A1

公开(公告)日：2020-02-05

申请号：EP18712899.6

申请日：2018-03-22

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft

发明人： LÜCKING, Ulrich ,  HOG, Daniel ,  CHRIST, Clara ,  SACK, Ulrike ,  SIEGEL, Franziska ,  LIENAU, Philip ,  WERBECK, Nicolas

IPC分类号： C07D401/12 ,  C07D239/30 ,  C07D498/04 ,  A61K31/519 ,  A61P9/00 ,  A61P35/00

公开(公告)号：EP3601236A1

公开(公告)日：2020-02-05

申请号：EP18712892.1

申请日：2018-03-22

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft

发明人： LÜCKING, Ulrich ,  HOG, Daniel ,  CHRIST, Clara ,  SACK, Ulrike ,  SIEGEL, Franziska ,  LIENAU, Philip ,  WERBECK, Nicolas

IPC分类号： C07D239/30 ,  C07D498/08 ,  C07D498/18 ,  C07D213/61 ,  A61K31/519 ,  A61P35/00 ,  A61P9/00

公开(公告)号：EP3395818A1

公开(公告)日：2018-10-31

申请号：EP18167649.5

申请日：2015-08-03

申请人： Bayer Pharma Aktiengesellschaft

发明人： WORTMANN, Lars ,  LÜCKING, Ulrich ,  LEFRANC, Julien ,  BRIEM, Hans ,  KOPPITZ, Marcus ,  EIS, Knut ,  VON NUSSBAUM, Franz ,  BADER, Benjamin ,  WENGNER, Antje-Margret ,  SIEMEISTER, Gerhard ,  BONE, Wilhelm ,  LIENAU, Philip ,  GRUDZINSKA-GOEBEL, Joanna ,  MOOSMAYER, Dieter ,  EBERSPÄCHER, Uwe ,  SCHICK, Hans

IPC分类号： C07D471/04

CPC分类号： A61K31/541 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/675 ,  A61K45/06 ,  C07D471/04 ,  C07D491/22 ,  C07D519/00 ,  C07F9/6561

摘要： The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib),

to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

公开(公告)号：EP3157914B1

公开(公告)日：2018-09-26

申请号：EP15730130.0

申请日：2015-06-17

申请人： Bayer Pharma Aktiengesellschaft

发明人： GRAHAM, Keith ,  KLAR, Ulrich ,  BRIEM, Hans ,  HITCHCOCK, Marion ,  BÄRFACKER, Lars ,  EIS, Knut ,  SCHULZE, Volker ,  SIEMEISTER, Gerhard ,  BONE, Wilhelm ,  SCHRÖDER, Jens ,  HOLTON, Simon ,  LIENAU, Philip ,  TEMPEL, René ,  SONNENSCHEIN, Helmut ,  BÁLINT, Jozsef ,  GRAUBAUM, Heinz

IPC分类号： C07D401/14 ,  C07D405/14 ,  C07D401/04 ,  C07D403/04 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/056 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D401/04 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/056

摘要： Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

公开(公告)号：EP3292107A1

公开(公告)日：2018-03-14

申请号：EP16721762.9

申请日：2016-05-02

申请人： Bayer Pharma Aktiengesellschaft

发明人： EIS, Knut ,  ACKERSTAFF, Jens ,  WAGNER, Sarah ,  BUCHGRABER, Philipp ,  SÜLZLE, Detlev ,  HOLTON, Simon ,  BENDER, Eckhard ,  LI, Volkhart ,  LIU, Ningshu ,  SIEGEL, Franziska ,  LIENAU, Philip ,  BAIRLEIN, Michaela ,  VON NUSSBAUM, Franz ,  HERBERT,Simon ,  KOPPITZ, Marcus

IPC分类号： C07D233/54 ,  C07D263/34 ,  C07D401/12 ,  C07D403/06 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D487/14 ,  A61K31/38 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/5025 ,  A61P35/00

CPC分类号： C07D233/90 ,  A61K31/4155 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/421 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/554 ,  A61K45/06 ,  A61P35/00 ,  A61P35/04 ,  C07D233/54 ,  C07D263/34 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12 ,  C07D487/04 ,  C07D487/10 ,  C07D487/14 ,  C07D491/107 ,  C07D495/10

摘要： The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredient.

公开(公告)号：EP3259251A1

公开(公告)日：2017-12-27

申请号：EP16704645.7

申请日：2016-02-16

申请人： Bayer Pharma Aktiengesellschaft

发明人： THEDE, Kai ,  BENDER, Eckhard ,  SCOTT, William, J. ,  GIESE, Anja ,  ZORN, Ludwig ,  LIU, Ningshu ,  MÖNNING, Ursula ,  SIEGEL, Franziska ,  GOLZ, Stefan ,  HÄGEBARTH, Andrea ,  LIENAU, Philip ,  PÜEHLER, Florian ,  BASTING, Daniel ,  SCHNEIDER, Dirk ,  MÖWES, Manfred

IPC分类号： C07D213/73 ,  C07D231/12 ,  C07D403/04 ,  C07D239/26 ,  C07D239/34 ,  C07D239/42 ,  C07D213/40 ,  C07D213/61 ,  C07D213/64 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61P35/00

CPC分类号： A61K31/5377 ,  A61K45/06 ,  C07D213/40 ,  C07D213/61 ,  C07D213/64 ,  C07D213/73 ,  C07D231/12 ,  C07D239/26 ,  C07D239/34 ,  C07D239/42 ,  C07D403/04

摘要： The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *Δ**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)-C(=O)** or *C(=O)-N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: -CH3, -O-CH3, -O-CHF2, -O-CF3, and -O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular, of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

公开(公告)号：EP3250567A1

公开(公告)日：2017-12-06

申请号：EP16701600.5

申请日：2016-01-25

申请人： Bayer Pharma Aktiengesellschaft

发明人： GRAHAM, Keith ,  KLAR, Ulrich ,  BRIEM, Hans ,  SCHULZE, Volker ,  SIEMEISTER, Gerhard ,  LIENAU, Philip ,  TEMPEL, René ,  BÁLINT, Jozsef

IPC分类号： C07D405/14 ,  C07D401/12 ,  C07D471/04 ,  A61K31/437 ,  A61P35/00

摘要： Compounds of formula (I), processes for their production and their use as pharmaceuticals.

公开(公告)号：EP3237417A1

公开(公告)日：2017-11-01

申请号：EP15817825.1

申请日：2015-12-21

申请人： Bayer Pharma Aktiengesellschaft

发明人： EIS, Knut ,  HARTUNG, Ingo ,  PETERSEN, Kirstin ,  LIENAU, Philip ,  BÖMER, Ulf

IPC分类号： C07D487/04 ,  A61K31/5025 ,  A61P35/00 ,  A61P37/00

CPC分类号： C07D487/04 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06

摘要： The present invention relates to 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl- substituted imidazopyridazine compounds of general formula (I) in which R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

摘要翻译： 本发明涉及通式（I）的6-羟基苯并呋喃基和6-烷氧基苯并呋喃基取代的咪唑并哒嗪化合物，其中R 1和R 2如权利要求中所定义，涉及制备所述化合物的方法，涉及用于制备所述化合物的中间体化合物 ，涉及包含所述化合物的药物组合物和组合以及涉及所述化合物用于制备用于治疗或预防疾病，特别是过度增殖和/或血管生成失调的药物组合物作为唯一药物或组合 与其他有效成分。

公开(公告)号：EP2909200B1

公开(公告)日：2016-11-23

申请号：EP13777070.7

申请日：2013-10-16

申请人： Bayer Pharma Aktiengesellschaft

发明人： LÜCKING, Ulrich ,  BÖHNKE, Niels ,  SCHOLZ, Arne ,  LIENAU, Philip ,  SIEMEISTER, Gerhard ,  BÖMER, Ulf ,  KOSEMUND, Dirk ,  BOHLMANN, Rolf ,  ZORN, Ludwig

IPC分类号： C07D207/44 ,  C07D233/88 ,  C07D401/12 ,  C07D405/14 ,  A61K45/06 ,  A61K31/506

CPC分类号： C07D401/12 ,  A61K31/506 ,  A61K45/06 ,  C07D207/44 ,  C07D233/88 ,  C07D405/14 ,  A61K2300/00

公开(公告)号：EP2909176B1

公开(公告)日：2016-07-20

申请号：EP13782670.7

申请日：2013-10-15

申请人： Bayer Pharma Aktiengesellschaft

发明人： LÜCKING, Ulrich ,  BÖHNKE, Niels ,  SCHOLZ, Arne ,  LIENAU, Philip ,  SIEMEISTER, Gerhard ,  BÖMER, Ulf ,  KOSEMUND, Dirk ,  BOHLMANN, Rolf ,  ZORN, Ludwig

IPC分类号： C07D213/74 ,  C07D405/14 ,  A61K31/506 ,  A61P9/00 ,  A61P31/12 ,  A61P35/00

CPC分类号： C07D213/74 ,  A61K31/444 ,  C07D405/14